May 20, 2026
This blog explores the history of studying macrophages for targeted oncologic therapies, and charts the journey of Pheast in overcoming historical challenges of previous targets by focusing on the highly overexpressed CD24 marker. The article dives into promising clinical data supporting Pheast’s lead asset, PHST001, as well as early preclinical signals for PHST677, a first-in-class CDH1 x Nectin-4 bispecific antibody drug conjugate. This differentiation strategy, according to the author, is what truly sets Pheast apart from the pack in this space.
Subscribers can read the full article here.